CommercialCoverageLow impact
08.01.88b, Allogeneic Processed Thymus Tissue-agdc (Rethymic®)
Independence Blue Cross·Allergy & Immunology, Oncology, Pediatrics·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Insurance policy 08.01.88b introduces new medical necessity criteria for Allogeneic Processed Thymus Tissue-agdc (Rethymic®), a specialized pharmacy product. This policy change establishes coverage requirements and criteria for this thymus tissue treatment.
Action Required
By November 17, 2025: Billing team should review the full policy details at the provided URL to understand specific medical necessity criteria for Rethymic® (Allogeneic Processed Thymus Tissue-agdc). Update prior authorization processes if required and ensure providers are aware of new coverage criteria. This affects specialized immunology treatments.